SELLAS to Present at UBS Virtual Global Healthcare Conference
May 07 2020 - 08:00AM
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the
“Company”), a late-stage clinical biopharmaceutical company focused
on the development of novel cancer immunotherapies for a broad
range of cancer indications, today announced that Angelos Stergiou,
M.D., ScD h.c., President and Chief Executive Officer of SELLAS,
will present a corporate overview at the UBS Virtual Global
Healthcare Conference on Monday, May 18, 2020 at 4:40 pm EDT (1:40
pm PDT).
To access a live webcast of the presentation,
please visit the Investors, Events and Presentations section of the
Company’s website at www.sellaslifesciences.com. A replay of the
webcast will be available on the Company’s website following the
live presentation.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical
biopharmaceutical company focused on the development of novel
cancer immunotherapeutics for a broad range of cancer indications.
SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed
from Memorial Sloan Kettering Cancer Center and targets the WT1
protein, which is present in an array of tumor types. GPS has
potential as a monotherapy or in combination to address a broad
spectrum of hematologic malignancies and solid tumor indications.
SELLAS’ second product candidate, nelipepimut-S (NPS), is a
HER2-directed cancer immunotherapy with potential for the treatment
of patients with early stage breast cancer with low to intermediate
HER2 expression, otherwise known as HER2 1+ or 2+, which includes
triple negative breast cancer patients, following standard of care.
For more information on SELLAS, please
visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking
statements. All statements other than statements of historical
facts are “forward-looking statements,” including those relating to
future events. In some cases, forward-looking statements can be
identified by terminology such as “plan,” “expect,” “anticipate,”
“may,” “might,” “will,” “should,” “project,” “believe,” “estimate,”
“predict,” “potential,” “intend,” or “continue” and other words or
terms of similar meaning. These statements include, without
limitation, statements related to the Company’s plans for clinical
development of for GPS, including the timing of clinical results,
and the potential for GPS as a drug development candidate, and its
business development efforts for NPS. These forward-looking
statements are based on current plans, objectives, estimates,
expectations and intentions, and inherently involve significant
risks and uncertainties. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with the COVID-19 pandemic and its impact
on the Company’s clinical plans and business strategy,
immune-oncology product development and clinical success thereof,
the uncertainty of regulatory approval, and other risks and
uncertainties affecting SELLAS and its development programs as set
forth under the caption “Risk Factors” in SELLAS’ Annual Report on
Form 10-K filed on March 13, 2020 and in its other SEC filings.
Other risks and uncertainties of which SELLAS is not currently
aware may also affect SELLAS’ forward-looking statements and may
cause actual results and the timing of events to differ materially
from those anticipated. The forward-looking statements herein are
made only as of the date hereof. SELLAS undertakes no obligation to
update or supplement any forward-looking statements to reflect
actual results, new information, future events, changes in its
expectations or other circumstances that exist after the date as of
which the forward-looking statements were made.
Investor Contacts Adam Holdsworth PCG Advisory
646-862-4607 adamh@pcgadvisory.com
Investor Relations SELLAS Life Sciences Group, Inc. 917-438-4353
info@sellaslife.com
Source: SELLAS Life Sciences Group
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Feb 2024 to Mar 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2023 to Mar 2024